Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.57 |
| ▸ | CTSK | P43235 | 4/20 | 0.57 |
| ▸ | PPARA | Q07869 | 9/20 | 0.56 |
| ▸ | PPARG | P37231 | 8/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | ITGAV | P06756 | 1/20 | 0.44 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22390650 | 1.00 | CTSS (0.57) | CTSSCTSKPPARAPPARGITGB3 | |
| SCHEMBL22390723 | 0.90 | CTSS (0.53) | CTSSCTSKPPARAPPARGITGB3 | |
| SCHEMBL22390724 | 0.90 | CTSS (0.53) | CTSSCTSKPPARAPPARGITGB3 | |
| SCHEMBL30220129 | 0.88 | CTSK (0.52) | CTSSCTSKPPARAPPARGITGB3 | |
| SCHEMBL955526 | 0.85 | PPARA (0.74) | CTSSCTSKPPARAPPARGACE | |
| SCHEMBL1312604 | 0.85 | PPARA (0.74) | CTSSCTSKPPARAPPARGACE | |
| SCHEMBL955527 | 0.85 | PPARA (0.74) | CTSSCTSKPPARAPPARGACE | |
| SCHEMBL29013104 | 0.85 | CTSS (0.56) | CTSSCTSKPPARAPPARGITGB3 | |
| SCHEMBL1514326 | 0.84 | CTSS (0.73) | CTSSCTSKPPARAPPARGITGB3 | |
| SCHEMBL9955736 | 0.84 | CTSS (0.73) | CTSSCTSKPPARAPPARGITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3935042-B1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC (KR) | 2024-08-28 | — | — | EP | disclosed |
| US-12071412-B2 | Caspase inhibitors and methods of use thereof | NOBO MEDICINE INC. (KR) | 2024-08-27 | — | — | US | disclosed |
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2023-08-10 | — | — | US | disclosed |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | HISTOGEN, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20200283396-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP1, CASP3, CASP7 | CTSS 66/4885CTSK 68/4885PPARA 3631/4885 |
| US-20200283396-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP1, CASP3, CASP7 | CTSS 66/4885CTSK 68/4885PPARA 3631/4885 |
| US-12071412-B2 | Caspase inhibitors and methods of use thereof | CASP1, CASP3, CASP7 | CTSS 66/4885CTSK 68/4885PPARA 3631/4885 |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | CASP1, CASP3, CASP7 | CTSS 66/4885CTSK 68/4885PPARA 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.